Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression Correlates Positively with Active Angiogenesis and Negatively with Basic Fibroblast Growth Factor Expression in Epithelial Ovarian Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2013 Dec 31

PMID 24374756

Citations 10

Authors

Sebastian Szubert

Dariusz Szpurek

Rafal Moszynski

Michal Nowicki

Andrzej Frankowski

Stefan Sajdak

Slawomir Michalak

Affiliations

Soon will be listed here.

Abstract

Purpose: The primary aim of this paper was to evaluate the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and its relationship with proangiogenic factors and microvessel density (MVD) in ovarian cancer.

Methods: The study group included 58 epithelial ovarian cancers (EOCs), 35 benign ovarian tumors, and 21 normal ovaries. The expression of EMMPRIN, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) was assessed by ELISA of tissue homogenates. Antibodies against CD105, CD31, and CD34 were used to immunohistochemically assess MVD.

Results: We have found significantly higher EMMPRIN expression in EOC than in benign ovarian tumors and normal ovaries. Similarly, the VEGF expression was higher in EOC than in benign ovarian tumors and normal ovaries. By contrast, bFGF expression was lower in EOC than in benign ovarian tumors and ovary samples. EMMPRIN expression in EOC was directly correlated with VEGF expression and CD105-MVD, but inversely correlated with bFGF expression. Grade 2/3 ovarian cancers had increased expression of EMMPRIN and VEGF, increased CD105-MVD, and lowered expression of bFGF compared to grade 1 ovarian cancers. Moreover, EMMPRIN expression was higher in advanced (FIGO III and IV) ovarian cancer.

Conclusions: The upregulation of EMMPRIN and VEGF expression is correlated with increased CD105-MVD and silenced bFGF, which suggests early and/or reactivated angiogenesis in ovarian cancer. Aggressive EOC is characterized by the following: high expression of EMMPRIN and VEGF, high CD105-MVD, and low expression of bFGF.

Citing Articles

Extracellular vesicle-mediated communication between CD8 cytotoxic T cells and tumor cells.

Huang Z, Liu X, Guo Q, Zhou Y, Shi L, Cai Q Front Immunol. 2024; 15:1376962.

PMID: 38562940 PMC: 10982391. DOI: 10.3389/fimmu.2024.1376962.

A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer.

Carroll M, Kaipio K, Hynninen J, Carpen O, Hautaniemi S, Page D Cancers (Basel). 2022; 14(17).

PMID: 36077825 PMC: 9454800. DOI: 10.3390/cancers14174291.

Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy.

Xu J, Cao W, Wang P, Liu H Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890175 PMC: 9318328. DOI: 10.3390/ph15070876.

Roles of Microvesicles in Tumor Progression and Clinical Applications.

Zhu S, Li S, Yi M, Li N, Wu K Int J Nanomedicine. 2021; 16:7071-7090.

PMID: 34703228 PMC: 8536885. DOI: 10.2147/IJN.S325448.

CD147 promotes epithelial-mesenchymal transition of prostate cancer cells via the Wnt/β-catenin pathway.

Fang F, Li Q, Wu M, Nie C, Xu H, Wang L Exp Ther Med. 2020; 20(4):3154-3160.

PMID: 32855684 PMC: 7444412. DOI: 10.3892/etm.2020.9058.

References

Riethdorf S, Reimers N, Assmann V, Kornfeld J, Terracciano L, Sauter G . High incidence of EMMPRIN expression in human tumors. Int J Cancer. 2006; 119(8):1800-10. DOI: 10.1002/ijc.22062. View

Liu Z, Hartman Y, Warram J, Knowles J, Sweeny L, Zhou T . Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells. Mol Cancer Res. 2011; 9(8):1008-17. PMC: 3157557. DOI: 10.1158/1541-7786.MCR-11-0043. View

du Bois A, Luck H, Meier W, Adams H, Mobus V, Costa S . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95(17):1320-9. DOI: 10.1093/jnci/djg036. View

Bergers G, Hanahan D . Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8(8):592-603. PMC: 2874834. DOI: 10.1038/nrc2442. View

Li R, Huang L, Guo H, Toole B . Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J Cell Physiol. 2001; 186(3):371-9. DOI: 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8. View

Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83. DOI: 10.1056/NEJMoa1104390. View

Cannistra S, Matulonis U, Penson R, Hambleton J, Dupont J, Mackey H . Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007; 25(33):5180-6. DOI: 10.1200/JCO.2007.12.0782. View

Sun J, Hemler M . Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001; 61(5):2276-81. View

Collinson F, Hutchinson M, Craven R, Cairns D, Zougman A, Wind T . Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res. 2013; 19(18):5227-39. PMC: 3780518. DOI: 10.1158/1078-0432.CCR-13-0489. View

10.

Malpica A, Deavers M, Lu K, Bodurka D, Atkinson E, Gershenson D . Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004; 28(4):496-504. DOI: 10.1097/00000478-200404000-00009. View

11.

Millimaggi D, Mari M, D Ascenzo S, Giusti I, Pavan A, Dolo V . Vasculogenic mimicry of human ovarian cancer cells: role of CD147. Int J Oncol. 2009; 35(6):1423-8. DOI: 10.3892/ijo_00000460. View

12.

Xing F, Saidou J, Watabe K . Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed). 2009; 15(1):166-79. PMC: 2905156. DOI: 10.2741/3613. View

13.

Sood A, Fletcher M, Zahn C, Gruman L, Coffin J, Seftor E . The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther. 2003; 1(6):661-4. DOI: 10.4161/cbt.316. View

14.

Millimaggi D, Mari M, DAscenzo S, Carosa E, Jannini E, Zucker S . Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia. 2007; 9(4):349-57. PMC: 1854851. DOI: 10.1593/neo.07133. View

15.

Tang Y, Nakada M, Kesavan P, McCabe F, Millar H, Rafferty P . Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005; 65(8):3193-9. DOI: 10.1158/0008-5472.CAN-04-3605. View

16.

Obermair A, SPEISER P, Reisenberger K, Ullrich R, Czerwenka K, Kaider A . Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett. 1998; 130(1-2):69-76. DOI: 10.1016/s0304-3835(98)00119-0. View

17.

Weidle U, Scheuer W, Eggle D, Klostermann S, Stockinger H . Cancer-related issues of CD147. Cancer Genomics Proteomics. 2010; 7(3):157-69. View

18.

Schauer I, Sood A, Mok S, Liu J . Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia. 2011; 13(5):393-405. PMC: 3084616. DOI: 10.1593/neo.101720. View

19.

Burger R . Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011; 121(1):230-8. DOI: 10.1016/j.ygyno.2010.11.035. View

20.

Dallas N, Samuel S, Xia L, Fan F, Gray M, Lim S . Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008; 14(7):1931-7. DOI: 10.1158/1078-0432.CCR-07-4478. View